This study is being conducted to evaluate the safety and the length of effect on platelet build-up in the arteries of Durlaza™ as compared to immediate-release Bayer® aspirin 81 mg or subject's current aspirin 81 mg of choice in patients who have Type 2 diabetes mellitus and cardiovascular disease or multiple risk factors of developing cardiovascular disease.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
41
Platelet and Thrombosis Research, LLC
Baltimore, Maryland, United States
change in platelet aggregation
Time frame: During the 26-hour hospital stays, outcomes will be measured at various timepoints
Reactive Hyperemia Index
Time frame: During the 26-hour hospital stays, outcomes will be measured at various timepoints
Safety as measured by the number and system class of adverse events reported in each treatment arm
Time frame: participants are followed for approximately 40 to 65 days once they start study medication
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.